Freya Biosciences

Freya Biosciences is a clinical-stage immunology company headquartered in Copenhagen, Denmark, developing disease-modifying microbial immunotherapies targeting inflammation and immune dysregulation in conditions affecting women. The company's lead programs focus on the underlying immune mechanisms driving infertility, preterm birth, and endometriosis — conditions where current treatments address only symptoms. Freya's scientific approach leverages the microbiome and endocannabinoid system to restore healthy immune function in the reproductive tract, with a Phase 2 pipeline backed by investors including Sofinnova Partners, the Bill & Melinda Gates Foundation, OMX Ventures, EIFO, and Angelini Ventures. Co-founded in 2020 by CEO Colleen Acosta and CSO Johan van Hylckama Vlieg, the company targets a critical gap in women's health where no approved disease-modifying treatments exist.